MCAS and Integrative Functional Medicine in San Antonio:An Evidence-Based Guide to LDN, Ketotifen, Cromolyn, and a Functional Medicine Approach to Mast Cell Activation Syndrome

https://www.youtube.com/watch?v=6pz_qlUIMK8

Yoon Hang Kim, MD, MPH  www.directintegrativecare.com

If you live in San Antonio and have been searching for answers about unexplained flushing, hives, brain fog, gut reactivity, food intolerances, dysautonomia, or anaphylaxis-like episodes that no one can quite explain, you may be navigating Mast Cell Activation Syndrome (MCAS). MCAS is one of the most underdiagnosed and most misunderstood conditions I see in my integrative and functional medicine practice.

MCAS is a condition in which mast cells—an essential part of the immune system—become dysregulated and inappropriately release mediators such as histamine, tryptase, prostaglandins, leukotrienes, and inflammatory cytokines. Because mast cells live in nearly every tissue, the symptoms can affect virtually every organ system: skin, gut, lungs, brain, cardiovascular system, and bladder. Patients are often told their labs are 'normal' and sent home with antihistamines that take the edge off but never address why the immune system became hair-triggered in the first place.

Conventional care for MCAS in San Antonio typically begins and ends with H1 and H2 blockers. A functional medicine approach goes deeper. It asks why the mast cells are misfiring—and uses targeted tools such as Low Dose Naltrexone (LDN), ketotifen, cromolyn sodium, an anti-inflammatory diet, and root-cause investigation to restore stability. This article walks through the framework I use at Direct Integrative Care, drawing on the work of MCAS specialists including Dr. Lawrence Afrin, Dr. Tania Dempsey, and Dr. Leonard Weinstock.

Why MCAS Demands an Integrative Functional Medicine Approach

MCAS is not a single disease with a single cause—it is a final common pathway. Mold exposure, tick-borne infections, post-viral syndromes (including Long COVID), gut dysbiosis, hypermobility/EDS, hormone shifts, and chronic stress can all push mast cells into a dysregulated state. A one-size-fits-all prescription rarely works. What does work is a layered strategy that combines symptom control with root-cause repair.

In my San Antonio integrative functional medicine practice, the framework I rely on includes:

• Identifying personal and environmental triggers unique to each patient

• Stabilizing mast cells with targeted prescription and natural agents

• Healing the gut and supporting the microbiome

• Reducing systemic inflammation through diet and lifestyle

• Investigating underlying drivers: mold, infections, dysautonomia, hormones, detox capacity

• Recalibrating the immune system with immunomodulatory therapies such as LDN

1. Low Dose Naltrexone (LDN): Recalibrating the Overactive Immune Response

Low Dose Naltrexone is one of the most important tools in my MCAS toolkit. At doses typically between 0.5 mg and 4.5 mg at bedtime, naltrexone briefly blocks opioid receptors. The body responds with a rebound surge of endorphins and enkephalins, which carry powerful immunomodulatory effects far beyond mood and pain regulation.

How LDN helps in MCAS

• TLR4 inhibition: LDN dampens Toll-like receptor 4 signaling and the downstream NF-κB inflammatory cascade.

• Cytokine rebalancing: Reduces pro-inflammatory IL-6 and TNF-α while supporting regulatory cytokines such as IL-10.

• T-cell modulation: T-cell microparticles are known mast cell activators; LDN reduces excessive T-cell dysfunction.

• Indirect mast cell stabilization: Rather than acting on mast cells directly, LDN recalibrates the immune environment they live in.

• Improved trigger tolerance: Patients often report a higher threshold for stress, infection, and allergen exposure.

The clinical evidence

The landmark 2018 BMJ Case Report by Weinstock and colleagues documented a patient with severe POTS and MCAS who achieved a 43% decrease in MCAS severity using LDN combined with IVIg. Survey data from the LDN Research Trust involving 116 MCAS patients found that approximately 60% reported improvement across multiple symptom domains. A 2025 published study rated LDN's mean benefit on overall health status at 5.6/10 in MCAS patients—meaningful in a population where most therapies fail.

LDN is not a cure. But over weeks to months, many patients experience meaningful reductions in fatigue, brain fog, flushing, joint pain, and inflammatory flare frequency. Because of the rebound effect on endorphins, LDN is dosed at bedtime and titrated slowly—particularly important in MCAS patients who are notoriously sensitive to medications.

2. Ketotifen: A Powerful Mast Cell Stabilizer

Ketotifen is a second-generation H1 antihistamine with potent mast cell stabilizing properties. In the United States it is available primarily through compounding pharmacies, and it has become a mainstay of functional medicine MCAS protocols because of its dual action.

Dual mechanism

• Prevents degranulation: Stabilizes calcium permeability in mast cell membranes, reducing release of histamine, tryptase, and prostaglandins.

• Blocks H1 receptors: Reduces downstream symptoms such as flushing, urticaria, itching, and gastrointestinal distress.

In the functional medicine model, ketotifen often serves as bridge therapy—buying patients meaningful symptom control while deeper drivers (mold, dysbiosis, infections, hormone imbalances) are systematically addressed. It is particularly well suited to systemic, skin, and respiratory symptom patterns.

Common starting doses are 0.5–1 mg at bedtime, titrated based on response and tolerance. Mild drowsiness is common at first and usually resolves within a week or two. Maximum therapeutic effect typically requires six to twelve weeks of consistent use—patience is essential.

3. Cromolyn Sodium: The GI Specialist

Cromolyn sodium is the gold standard for GI-predominant MCAS. Its great advantage is that less than 1% is absorbed systemically, which means it acts almost entirely on the mast cells lining the gut. This makes it both highly targeted and remarkably well tolerated.

Unlike ketotifen, cromolyn has no antihistamine activity—it is a pure mast cell stabilizer. It inhibits both immediate and late-phase mediator release and is particularly effective for abdominal pain, nausea, bloating, food-triggered reactions, and chronic diarrhea. It is available as Gastrocrom oral solution or can be compounded into capsules for patients sensitive to the liquid formulation.

4. The Anti-Inflammatory Diet: Lowering the Baseline Fire

Food is either medicine or fuel for the fire. Because mast cell activation is amplified by inflammatory foods and intestinal hyperpermeability ('leaky gut'), nutrition is foundational—not optional—in any serious MCAS protocol.

Core dietary principles

• Eliminate high-histamine foods: Fermented foods, aged cheeses, alcohol, cured meats, and leftovers can all amplify symptoms.

• Avoid common allergens and irritants: Gluten, dairy, soy, and artificial additives are frequent mast cell aggravators.

• Choose whole, nutrient-dense foods: Fresh organic vegetables and lower-histamine fruits (blueberries, zucchini, leafy greens), wild-caught fish rich in omega-3s, healthy fats (olive oil, avocado, coconut oil), and clean protein from pasture-raised sources.

Supportive supplements

• Quercetin: A bioflavonoid that inhibits mast cell release of histamine, tryptase, and inflammatory cytokines. Typical doses range from 500–1,000 mg daily, with a strong safety profile.

• Vitamin C: Enhances diamine oxidase (DAO) activity and lowers circulating histamine. Typical doses range from 500–2,000 mg daily.

• DAO enzymes: Pig kidney–derived DAO supplements taken before meals help break down dietary histamine.

• Luteolin: A flavonoid with particular value for neuroinflammatory MCAS presentations, often combined with quercetin.

5. Looking for Root Causes: The Functional Medicine Difference

Stabilizing mast cells is necessary, but it is not sufficient. A functional medicine workup for MCAS in San Antonio looks systematically at the underlying terrain that pushed the immune system into dysregulation in the first place. In my practice, this typically includes evaluating gut permeability and microbiome health, screening for mold and mycotoxin exposure (CIRS), assessing for tick-borne infections, reviewing hormone and adrenal balance, examining detoxification pathways, and considering genetic factors such as MTHFR and HNMT variants that affect histamine metabolism.

Patients with hypermobility spectrum disorders or Ehlers-Danlos syndrome deserve special attention—the triad of MCAS, POTS, and hEDS is increasingly recognized and requires a coordinated approach. So does post-viral MCAS following COVID-19, which has become one of the most common new presentations I see.

Clinical Algorithm: Matching Treatment to Phenotype

Not every MCAS patient looks the same, and the right starting agent depends on the dominant symptom pattern. The table below summarizes how I think about matching therapy to phenotype.

Patient Phenotype	First-Line Agent	Add-On Therapy	Clinical Rationale
GI-Predominant	Cromolyn Sodium	LDN, DAO enzymes	<1% systemic absorption; targets gut mast cells directly
Skin / Respiratory	Ketotifen	H1/H2 blockers, Quercetin	Dual mechanism: stabilizer + H1 antagonist
Neuroinflammatory	LDN	Ketotifen, Luteolin	TLR4 blockade; microglial modulation
Vasomotor / POTS	LDN + H1/H2 blockers	Methylene Blue (emerging)	Nitric oxide pathway modulation for flushing
Multi-System / Refractory	Combination therapy	IVIg, hydroxycarbamide	Immunomodulatory combinations

Why San Antonio Patients Choose Dr. Kim

San Antonio is a vibrant and growing medical community, but conventional care still struggles with complex chronic illness. MCAS patients in particular often spend years bouncing between specialists before finding someone who recognizes the pattern. Direct Integrative Care offers a different model:

• Membership-based, no insurance: Time and attention rather than rushed visits driven by insurance billing codes.

• Telemedicine across Texas: Convenient virtual care for patients in San Antonio, Austin, the Hill Country, and beyond.

• Functional medicine training: Board-certified preventive medicine with formal training in integrative and functional medicine through the University of Arizona under Dr. Andrew Weil.

• LDN expertise: Two decades of experience with Low Dose Naltrexone, including authorship of multiple LDN articles and leadership of an LDN community of more than 9,000 members.

• Whole-person approach: Integration of nutrition, supplements, prescription therapies, stress management, and root-cause investigation in one coordinated plan.

Final Thoughts

Managing MCAS requires more than suppressing symptoms. The functional medicine model offers a systems-based approach, aiming to rebalance the immune system, identify and remove triggers, and restore long-term resilience. While the therapies discussed here lack the massive Phase III trials of conventional drugs, they are widely used by leading MCAS specialists because of their biological plausibility, favorable safety profiles, and consistent clinical results.

If you are in San Antonio or elsewhere in Texas and you suspect MCAS may be part of your story, you do not have to navigate it alone. With the right framework, the right tools, and an experienced guide, meaningful improvement is possible.

MEDICAL DISCLAIMER

This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. MCAS is a complex, multi-system condition that requires individualized evaluation. Do not start, stop, or change any medication, supplement, or therapy—including LDN, ketotifen, cromolyn sodium, or compounded medications—without consulting a qualified healthcare provider familiar with your medical history. If you are experiencing anaphylaxis or a severe reaction, seek emergency care immediately.

Schedule a Consultation

To explore whether a functional medicine approach to MCAS is right for you, visit www.directintegrativecare.com or call (210) 981-6106. Direct Integrative Care is a membership-based telemedicine practice serving patients in Texas, Iowa, Illinois, Missouri, Georgia, and Florida.

About the Author

Yoon Hang "John" Kim, MD, MPH is a board-certified preventive medicine physician with additional certification in integrative and holistic medicine. He is a UCLA-trained medical acupuncturist, an Osher Fellow at the University of Arizona under Dr. Andrew Weil, an Institute for Functional Medicine scholar, and a recognized LDN expert and author. He is the founder of Direct Integrative Care and leads the LDN Support Group community of more than 9,000 members.

Selected References

Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports 2018;2018:bcr-2017-221405.

Weinstock LB, Afrin LB. Use of low dose naltrexone and hydroxycarbamide for mast cell disorders (ISM, MCAS, HaT). Journal of Cancer Prevention & Current Research 2025;16(1):12–15.

Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, Afrin LB. Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedeberg's Archives of Pharmacology 2016;389(7):671–694.

Afrin LB, Weinstock LB. Oral cromolyn sodium therapy for mast cell activation syndrome. American Journal of the Medical Sciences 2014;347(6):500–502.

Toljan K, Vrooman B. Low-dose naltrexone (LDN)—Review of therapeutic utilization. Medical Sciences 2018;6(4):82.

Theoharides TC, Tsilioni I, Bawazeer M. Mast cells, neuroinflammation and pain in fibromyalgia syndrome. Frontiers in Cellular Neuroscience 2019;13:353.

SEO Keywords: MCAS San Antonio, Integrative Functional Medicine San Antonio, Mast Cell Activation Syndrome San Antonio, MCAS specialist Texas, LDN San Antonio, ketotifen MCAS, cromolyn sodium MCAS, functional medicine MCAS, integrative medicine San Antonio, MCAS telemedicine Texas, POTS MCAS hEDS, histamine intolerance San Antonio, low dose naltrexone MCAS, Direct Integrative Care.

ep forward is a victory.